.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BX18_Dorzagliatin.Dorzagliatin .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BX18_Dorzagliatin.Dorzagliatin| name: | Dorzagliatin |
| ATC code: | A10BX18 | route: | oral |
| n-compartments | 2 |
Dorzagliatin is a novel, dual-acting glucokinase activator developed for the treatment of type 2 diabetes mellitus. It acts to enhance glucose homeostasis by improving both pancreatic beta-cell function and hepatic glucose uptake. Dorzagliatin is approved for use in China for patients with type 2 diabetes.
Pharmacokinetic parameters observed in healthy Chinese adult subjects after single oral administration.
Zhu, D, et al., & Chen, L (2018). Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study. The lancet. Diabetes & endocrinology 6(8) 627–636. DOI:10.1016/S2213-8587(18)30105-0 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29735394